Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939540 | 1.00 | AR (0.37) | ARPOLBMMP13KDM4EMCOLN3 | |
| SCHEMBL30939568 | 0.89 | ELANE (0.31) | — | |
| SCHEMBL9904640 | 0.89 | ELANE (0.31) | — | |
| SCHEMBL19853468 | 0.89 | — | — | |
| Aut-00206 SCHEMBL9904925 | 0.89 | AR (0.36) | ARPOLB | |
| SCHEMBL21857901 | 0.87 | AR (0.31) | AR | |
| SCHEMBL9905038 | 0.85 | AR (0.41) | ARPOLBMMP13KDM4EMCOLN3 | |
| SCHEMBL21953190 | 0.84 | KDM4E (0.30) | KDM4E | |
| SCHEMBL23786782 | 0.84 | AR (0.31) | AR | |
| SCHEMBL21610274 | 0.83 | NPC1 (0.32) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | claimed |
| US-10835534-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-11-17 | — | — | US | claimed |
| US-10555945-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-02-11 | — | — | US | claimed |
| US-20190000849-A1 | NOVEL COMPOUNDS | AUTIFONY THERAPEUTICS LIMITED | 2019-01-03 | — | — | US | claimed |
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-01-03 | — | — | US | claimed |
| EP-3386506-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | Autifony Therapeutics Limited (GB) | 2018-10-17 | — | — | EP | claimed |
| US-10098881-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-10-16 | — | — | US | claimed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | claimed |
| EP-2852588-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | claimed |
| WO-2017098254-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-15 | — | — | WO | claimed |
| US-9669030-B2 | Hydantoin derivatives as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | claimed |
| EP-2788339-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-09 | — | — | EP | claimed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | claimed |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | US | claimed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | claimed |
| EP-2788339-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | claimed |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2025-01-16 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | AR 4418/4885POLB 4505/4885MMP13 1635/4885 |
| US-20190000849-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | AR 4441/4885POLB 4214/4885MMP13 4544/4885 |
| US-10835534-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | AR 4256/4885POLB 3836/4885MMP13 4302/4885 |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCND3, KCNA3, KCNK3 | AR 4831/4885POLB 4349/4885MMP13 1968/4885 |
| US-20160317537-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | AR 4593/4885POLB 3696/4885MMP13 4640/4885 |
| US-10555945-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | AR 4256/4885POLB 3836/4885MMP13 4302/4885 |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | AR 4434/4885POLB 4542/4885MMP13 1693/4885 |
| US-20140323508-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | AR 4441/4885POLB 4214/4885MMP13 4544/4885 |
| US-10098881-B2 | Compounds | FANCI, CYFIP1, ZFX | AR 4582/4885POLB 565/4885MMP13 4607/4885 |
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | AR 4819/4885POLB 1145/4885MMP13 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.